David M. Kofler

Koeln, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.

Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.

Journal: Lancet (London, England)

Published: August 22, 2023

Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial.

Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial.

Journal: RMD open

Published: July 27, 2023

Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study.

Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study.

Journal: European journal of neurology

Published: June 29, 2023

Treatment of rheumatoid arthritis with baricitinib or upadacitinib is associated with reduced scaffold protein NEDD9 levels in CD4+ T cells.

Treatment of rheumatoid arthritis with baricitinib or upadacitinib is associated with reduced scaffold protein NEDD9 levels in CD4+ T cells.

Journal: Physiological reports

Published: May 18, 2023

Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.

Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.

Journal: The Lancet. Rheumatology

Published: February 01, 2023

Editorial: Dysregulation of Th17 and Treg cells in autoimmune diseases.

Editorial: Dysregulation of Th17 and Treg cells in autoimmune diseases.

Journal: Frontiers in immunology

Published: January 26, 2023

Reply.

Reply.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: January 01, 2023

Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis.

Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis.

Journal: RMD open

Published: September 25, 2022

Latest news on RA-ILD

Latest news on RA-ILD

Journal: Pneumologie (Stuttgart, Germany)

Published: September 14, 2022

High increase in levels of lipoprotein(a) in plasma of patients with rheumatoid arthritis after COVID-19.

High increase in levels of lipoprotein(a) in plasma of patients with rheumatoid arthritis after COVID-19.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: August 08, 2022

Tocilizumab for the Treatment of Familial Mediterranean Fever-A Randomized, Double-Blind, Placebo-Controlled Phase II Study.

Tocilizumab for the Treatment of Familial Mediterranean Fever-A Randomized, Double-Blind, Placebo-Controlled Phase II Study.

Journal: Journal of clinical medicine

Published: August 01, 2022

Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.

Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.

Journal: The Lancet. Rheumatology

Published: July 25, 2022

Showing 1-12 of 31

Last Updated: 09/26/2026